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MicroRNAs in inflammatory lung disease - master
regulators or target practice?
Irene K Oglesby, Noel G McElvaney†, Catherine M Greene*†
Abstract
MicroRNAs (miRNAs) have emerged as a class of regulatory RNAs with immense significance in numerous
biological processes. When aberrantly expressed miRNAs have been shown to play a role in the pathogenesis of
several disease states. Extensive research has explored miRNA involvement in the development and fate of
immune cells and in both the innate and adaptive immune responses whereby strong evidence links miRNA
expression to signalling pathways and receptors with critical roles in the inflammatory response such as NF-B and
the toll-like receptors, respectively. Recent studies have revealed that unique miRNA expression profiles exist in
inflammatory lung diseases such as cystic fibrosis, chronic obstructive pulmonary disease, asthma, idiopathic pul-
monary fibrosis and lung cancer. Evaluation of the global expression of miRNAs provides a unique opportunity to
identify important target gene sets regulating susceptibility and response to infection and treatment, and control
of inflammation in chronic airway disorders. Over 800 human miRNAs have been discovered to date, however the
biological function of the majority remains to be uncovered. Understanding the role that miRNAs play in the mod-
ulation of gene expression leading to sustained chronic pulmonary inflammation is important for the development
of new therapies which focus on prevention of disease progression rather than symptom relief. Here we discuss
the current understanding of miRNA involvement in innate immunity, specifically in LPS/TLR4 signalling and in the
progression of the chronic inflammatory lung diseases cystic fibrosis, COPD and asthma. miRNA in lung cancer and
IPF are also reviewed.
Introduction
Inflammatory lung diseases encompass a range of condi-
tions which can be divided into acute and chronic dis-
eases. Acute inflammatory lung diseases, for example
pneumonia, in large part are triggered by environmental
stimuli without the contribution of a genetic factor. Air-
way disorders associated with persistent inflammation
such as cystic fibrosis (CF), chronic obstructive pulmon-
ary disease (COPD) and asthma are classed as chronic
conditions and are influenced by a combination of envir-
onmental, genetic and epigenetic components [1]. Infec-
tions causing severe systemic inflammation, depending
on the magnitude of the initial stimulus can be short
lived dissipating within days or weeks [2], whereas the
sustained inflammation observed in CF, COPD and
asthma can elicit deleterious effects leading to lung tissue
damage, a constant need for medication and poor quality
of life. Dysregulated inflammation is also observed in
lung cancer and IPF and collectively with CF, COPD and
asthma these conditions account for a huge percentage
of deaths worldwide and hence there is an increasing
need for the development of new therapies.
Elements of signalling pathways activated during the
progression of chronic inflammation in the lung repre-
sent a vast area for miRNA studies. Although still in its
infancy the involvement of miRNA in inflammatory
lung diseases is becoming rapidly apparent (Table 1).
Several investigators have implicated negative feedback
control of inflammation via both regulators of inflam-
matory signalling and miRNA induction which we refer
to later on in the review. We also discuss the biogenesis
of miRNA and their role in the acquired and innate
immune response highlighting specifically those linked
to LPS/TLR4 signalling. We describe inflammatory lung
disease in CF, COPD and asthma and explore what is
currently known about miRNA and its role in the
pathogenesis of these debilitating conditions along with
a brief look at miRNA in lung cancer and IPF.
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miRNA background
The discovery of miRNA is considered one of the major
breakthroughs of the last decade. However they were
probably first mentioned in the 1960’s when Britten and
Davidson proposed the existence of “activator” RNAs
transcribed from redundant genomic regions [3]. In 1993
the first miRNA lin-4 was discovered in C.elegans [4] and
it wasn’t until eight years later that again in C.elegans the
highly conserved let-7 was found to be crucial for devel-
opmental timing [5]. The term microRNA was coined
when a large number of these small RNAs with potential
regulatory roles were discovered in 2001 [6]. The follow-
ing year established the presence of miRNAs in plants
[7]. Subsequently miR-15 and miR-16 were shown to be
deleted or down-regulated in chronic lymphocytic leuke-
mias [8] suggesting miRNA involvement in cancer in
humans.
MiRNAs are small, endogenous RNAs, approximately
20-25 nucleotides long which negatively regulate gene
expression at a post-transcriptional level. They exert
direct effects on gene expression by inducing mRNA
degradation or translation inhibition and recently have
been reported to act by indirect means through global
effects on methylation or targeting of transcription fac-
tors [9,10]. Up-regulation of gene translation by miRNAs
has also been reported albeit to a lesser extent, where
miR-369-3 for example, has been shown to switch from
mRNA repression to activation in quiescent cell popula-
tions [11]. Interest in miRNAs over the past decade has
increased exponentially uncovering their importance in
biological processes such as development, proliferation
and apoptosis. Relatively few miRNAs have been studied
in detail and hence the precise biological relevance of the
majority remains to be uncovered. It is estimated that up
to one third of the human genome may be subject to reg-
ulation by miRNAs. Expression levels vary greatly among
tissues and it is believed that dysregulation of miRNAs
can contribute to disease pathology [12].
miRNA - origin, processing and target selection
Primary miRNA (pri-miRNA) originate in the nucleus as
single long transcripts up to 1000 nucleotides long which
can be processed by the RNase III enzyme Drosha and
the RNA binding protein DGCR8 into pre-cursor hairpin
structures ~ 70-100nt long termed “pre-miRNA” [13-15].
Transport to the cytoplasm is via Exportin 5 where the
pre-miRNA is further processed by Dicer into a miRNA
duplex consisting of the mature miRNA and the so called
miRNA* strand (which is generally degraded) [16]. Incor-
poration of the mature miRNA into a miRNA-induced
silencing complex (miRISC) is facilitated by Argonate
protein involvement and transport to the target mRNA
has recently been reported to involve importin 8 [17]
Table 1 Selected miRNA implicated in inflammatory lung disease
miRNA Tissue/Cell Type Species Condition/treatment Validated Target Genes References
Let-7d Lung biopsies Human IPF HMGA2 [124]
miR-21 Whole lung Mouse Asthma IL-12p35 [94]
Macrophages
Dendritic cells
Lung biopsies Human IPF Smad, Smad7 [125]
miR-126 Primary bronchial epithelial cells Human CF TOM1, Tollip [112]
Lower airway tissue Mouse Asthma OBF.1 [120]
miR-133a Bronchial smooth muscle cells Human Asthma RhoA [97]
miR-146a Lung alveolar epithelial cells Human IL-1b IL-8, RANTES [67]
miR-218 Primary bronchial epithelial cells Human CSE MAFG [87]
miR148a,b, Human miR-152 Primary bronchial epithelial cells Asthma HLA-G [24]
# Let-7c miR-34c miR-222 Whole lung Rat CSE ND [86]
miR-26b, 27a, miR-31*, 96, Primary bronchial epithelial cells Human DEP ND [88]
miR-135b,274a,
miR-338-5p, 494,
miR-513a-5p, b, c,
miR-923
Let-7a, b, f, Whole lung Mouse CSE ND [85]
miR-26a, 30b, c,
miR-34b, 99b, 122a,
miR-124a, 125a, b, 140,
miR-192, 431
CSE; cigarette smoke extract, ND; not determined, DEP; diesel exhaust particulate, # 3 of 24 down-regulated miR’s validated by qRT-PCR.
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(Figure 1). Single miRNA can exist in introns and exons
of so called host genes, whilst certain groups of miRNAs
are present in clusters in the genome for example the
miR-17-92 family. Within each miRNA there exists a 2-8
nucleotide “seed region” thought to be critical for target
selection [18]. Mature miRNAs use this seed region to
bind selectively to miRNA recognition elements (MRE)
within the 3’ untranslated region (3’UTR) of target
mRNAs. Different target genes may contain several
MREs and therefore be regulated by numerous miRNAs.
The number of and distance between MREs are consid-
ered important for the biological activity of miRNAs.
Targeting and subsequent repression of transcripts may
also occur at the 5’UTR with equal efficacy [19]. How-
ever, the majority of studies have revolved around deter-
mination of miRNA:mRNA interactions at the 3’UTR.
miRNA regulation
The matter of miRNA regulation and expression has
been subject to much speculation with multiple levels
of control being identified in recent studies. O’Connell
et al describe three levels of control, namely at the
stages of “(i) transcription, (ii) processing and (iii) sub-
cellular localisation” [20]. Stage (i) includes induction
of miRNA expression by transcription factors in
response to inflammatory stimuli and cellular stresses,
stage (ii) impaired processing may be due to dicer
inhibition [21] or post-transcriptional modifications
[22] and finally stage (iii) is where miRNA can localise
to stress granules and p-bodies; a process which is
poorly understood at this time. Epigenetic mechanisms
controlling miRNA expression have been described
whereby down-regulation of miR-126 for example can
be induced by inhibitors of DNA methylation and his-
tone deacetylation [23]. Alterations in miRNA function
can also occur as a result of single nucleotide poly-
morphisms (SNPs). Tan et al reported compromised
binding of miR-148a, -148b and -152 to the asthma
susceptibility gene HLA-G due to the presence of a
polymorphism in the 3’UTR [24].
Figure 1 Representation of miRNA induction and biogenesis. Induction of miRNA expression occurs via transcription factors and other
regulatory influences. Primary miRNA transcripts (pri-miRNA) produced in the nucleus are generally processed by Drosha and DGCR8 into pre-
miRNA hairpin structures and transported to the cytoplasm by Exportin 5. The pre-miRNA is processed by Dicer into a miRNA duplex where the
mature miRNA guide strand is incorporated into a miRNA-induced silencing complex (miRISC) and the miRNA* strand is degraded. Incorporation
into miRISC is facilitated by AGO proteins. Importin 8 aids subsequent transport of the miRNA to the target mRNA where binding to the 3’UTR
occurs resulting in translational repression or degradation.
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The majority of miRNA-induced changes in gene
expression are subtle exerting a modest 2-3 fold repres-
sion of targets which can hamper elucidation of miRNA
function [25]. However, the most important miRNA-
regulated effects appear to occur as a result of miRNA
down-regulation or deletion. For example, miR-126 was
shown to be essential for maintenance of vascular integ-
rity and angiogenesis in vivo whereby targeted deletion
(mice) or knockdown (zebrafish) resulted in partial
embryonic lethality or leaky vessels and haemorrhaging,
respectively [26,27]. MiR-126 and miR-335 are specifi-
cally lost as breast cancer cells move towards metastasis
and consequently these miRNAs have been suggested to
function as metastasis suppressor miRNAs in human
breast cancer. Their re-introduction into breast cancer
cells in vivo led to reduced tumor growth, proliferation
and inhibition of invasion [28]. It is also evident that
changes in gene expression in one cell type may not
occur in another, as illustrated in zebrafish by Mishima
et al [29], where miR-430 repression of a subset of tar-
get genes in somatic cells had no effect on the same
genes in primordial germ cells. This supports evidence
for cell specific miRNA participation in different path-
ways and also draws attention to the regulation of
miRNA by multiple mechanisms. One such miRNA reg-
ulatory mechanism recently described opens a poten-
tially vast area of study whereby previously ignored
“Junk” pseudogenes may act as decoys for miRNA
thereby preserving expression of their functionally rele-
vant counterpart. Poliseno et al reported that the pesu-
dogene PTENP1 of tumor suppressor PTEN, presents a
conserved region in its 3’UTR to which miRNA bind,
leading to de-repression of PTEN and enhanced tumor
suppressor activity [30]. Recent work in C.elegans and
plants have uncovered proteins that regulate miRNA
turnover [31,32], however this has not yet been demon-
strated in mammals.
miRNA - immune response and TLR signalling
Acquired immunity
This arm of the immune response mediated by T and B
lymphocytes is probably one of the best characterised
developmental systems in mammals. Many investigators
have described an integral role for miRNA in acquired
immunity and these studies have been extensively
reviewed [20,33-36]. The importance of miRNA in both
T and B cell development has been demonstrated via dis-
ruption of miRNA processing machinery. For example,
T-cell specific deletion of dicer results in reduced T cell
numbers and a progression towards autoimmune pathol-
ogy [37] and in B-cells dicer knockout impairs pro- to
pre-B cell progression almost completely accompanied
by increased level of the pro apoptotic protein Bim [38].
MiR-150 has been reported to block production of
mature B cells [39] via dysregulation of transcription fac-
tor C-myb which elicits critical control during multiple
steps of lymphocyte differentiation [40]. Over-expression
of miR-181 causes a marked in increase in B cells num-
bers with no effect on T cells or myeloid cells [41] and
can regulate sensitivity of T cell receptor signalling to
antigens [42]. The importance of miR-155 in mainte-
nance of a normal immune response was highlighted by
Rodriguez et al who observed that mice deficient in miR-
155 display diminished B and T cell responses and
favored differentiation of helper T (TH) cells towards a
TH2 response [43].
Innate immunity
The innate immune response is a complex, highly orga-
nised first line of host defense initiated upon exposure to
invading pathogens and allergens. Carefully balanced
resolution of inflammation triggered by infection is criti-
cal to the prevention of chronic disease states. In the air-
ways cellular components such as alveolar macrophages,
neutrophils and epithelial cells have key functions in this
process [44]. Once thought to be a non-specific response
to keep infection at bay while the adaptive immune
system prepared appropriately it is now known to be a
prerequisite for initiation of several adaptive immune
response components. Toll like receptors (TLRs) are a
family of pattern recognition receptors that play an
essential role in innate immunity by responding to
microbial antigens such as lipopolysaccharide (LPS) and
initiating signalling cascades that culminate in pro-
inflammatory gene expression, principally via activation
of the transcription factors NFkB and the IRFs [45-47].
However, whilst crucial for pathogen clearance, under or
over-exuberant TLR signalling can be deleterious to the
host leading to the pathogenesis of chronic inflammatory
conditions [48,49]. In the lung TLRs are expressed by
immune cells and also epithelial cells [50]. A number of
reports have provided evidence of miRNA involvement
in immune cell development and in regulation of the
innate immune response in part via establishment of a
link between TLR signalling, miRNA expression and acti-
vation of inflammatory pathways [33-36,51-53]. Both
bacterial and viral ligands of the TLRs can induce the
expression of several miRNA as can inflammatory cyto-
kines produced as a direct result of TLR stimulation.
LPS/TLR4 signalling
Of the TLRs characterised to date, TLR4 in particular
has been the subject of the majority of studies where a
firm link between miRNA expression and TLR4 signal-
ling pathways is now recognised, (depicted in Figure 2).
The vast majority of studies have been performed in
macrophages (murine and human, in vitro and in vivo)
and to a lesser extent, neutrophils, PBMCs and epithelial
cells. LPS, one of the major ligands for TLR4 has been
associated with induction of several miRNA including
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miR-155, -146, -9 and -21 to name a few, which were
shown to target SHIP1, IRAK1/TRAF6, NF-B1, and
tumor suppressor PDCD4 respectively [54-57]. Expres-
sion of miR-155 can also be induced by additional TLR
ligands and a plethora of pro-inflammatory cytokines
[53] and in the context of inflammatory lung disease
mice deficient in miR-155 display immunodeficiency
and substantial airway remodelling [43]. Notably, the
position of the Bic/miR-155 gene in humans is located
on chromosome 21q21 mapping to a region of asthma
and pollen sensitivity [58,59]. Up-regulation of miR-9
expression shown to occur upon treatment with TLR2,
4, 7 and 8 agonists, IL-1b and TNF-a but not IFNg was
the only miRNA found to be differentially expressed in
both human neutrophils and monocytes following sti-
mulation with LPS [54].
Direct regulation of TLR4 by let-7i in human bilary
epithelial cells was reported by Chen et al who showed
that in the presence of LPS, let-7i expression is reduced in
a MyD88/NF-B dependent manner accompanied by a
concomitant increase in TLR4 protein. Two other mem-
bers of the let-7 family detected in these cells (let-7b and
let-7g) are also predicted to target TLR4 [60]. Contrary to
this, let-7a has been shown to be induced following LPS
stimulation in primary human macrophages [61]. The
same study demonstrated an LPS-induced decrease in
Figure 2 Selection of miRNA implicated in the TLR4 signalling pathway. TLR4 signals via MyD88 and TIRAP/MAL to IRAKs 1 and 4. The
TOM1/Tollip complex and SOCS1 are negative regulators of this pathway. The signal is transduced via TRAF6, TAK1 and IKK leading to activation
of NF-B via dissociation of IB. B-Ras2B is an IB inhibitor. miRNA targeting components of TLR4 signalling are shown in boxes. MiR-145 [126].
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miR-125b whereby the net effect of LPS regulation of
these miRNA resulted in inhibition of B-Ras2, an inhibi-
tor of IB. Pre-treatment with 17b Estradiol abrogated the
effects of LPS and was shown to suppress NF-B activa-
tion through induction of B-Ras2 via regulation of let-7a
and miR125b, suggesting estrogen mediated regulation of
miRNAs may be an important factor in control of inflam-
mation [61]. Let-7a induction was observed to be NF-B
dependent whereas the LPS-induced decrease in miR-
125b expression was independent of this pathway. Sup-
porting these findings Androlidaki et al reported that LPS
suppression of miR-125b is dependent on Akt signalling in
murine macrophages both in vitro and in vivo [62].
Negative feedback control of inflammation
Various means of intracellular and extracellular negative
control of inflammation for the maintenance of a balanced
response to TLR signalling exist. Endogenously, these
include decoy molecules that compete for binding to
TLRs such as soluble TLRs (sTLRs) [63] and a broad spec-
trum of intracellular molecules ranging from nuclear
receptors to proteases, kinases, transmembrane proteins,
ubiquitin-modifying and adaptor proteins [64]. Emerging
data on the role of miRNA in the immune response indi-
cates that their induction and regulation may play an
important role in the termination of inappropriate signal-
ling. For example TNF-a mediated induction of miR-31
and miR-17-3p target endothelial adhesion molecules E-
selectin and ICAM-1 respectively, which are both induced
by TNF-a thereby providing negative feedback control of
inflammation [65]. Another recent study to examine the
effects of IL-10 (a potent anti-inflammatory cytokine
poorly expressed in asthma) on TLR4 signalling demon-
strates that IL-10 can suppress LPS-induced miR-155
expression in a STAT3-dependent manner leading to an
increase in SHIP1 in bone marrow derived cells and in
human PBMCs. LPS is known to induce IL-10 and nega-
tively impact on this pathway by switching off the inflam-
matory response, so again this suggests a feedback loop
whereby induction of IL-10, promoted by LPS, keeps LPS-
induced miR155 expression in check. IL-10 was found to
have no effect on two other LPS induced miRNA - miR-
146a and miR-21 [66].
A role for miR-146 in “fine tuning” of the innate
immune response was described by Taganov et al when
they found that LPS-induced increased expression of
miR-146a was driven by NF-B in the monocytic cell line
THP-1 and negatively regulates IRAK1 and TRAF6, two
key adaptor molecules downstream of TLR and IL-1R
signalling, again illustrating a negative feedback control
loop [57]. Increased expression of miR-146a was also
induced upon treatment with TNF-a and IL-1b to a les-
ser extent and stimulation with other TLR ligands
revealed up-regulation in response to TLR2 and TLR5
activation but not by TLR3, 7 and 9 ligands [57]. In
human alveolar epithelial cells stimulation with IL-1b
elicited a rapid increase in miR-146a expression and to a
lesser degree miR-146b, corresponding to a decrease in
the expression of pro-inflammatory chemokines IL-8 and
RANTES, which the authors again propose as negative
feedback control of inflammation. Incidentally neither
IL-8 nor RANTES are predicted to contain binding sites
for miR-146a. Examination of miR-146 expression in pri-
mary bronchial epithelial cells revealed a comparable
increase in IL-1b-induced levels of miR-146a however
miR-146b was not detected in these cells [67].
miRNA and inflammatory lung disease
miRNA in lung cancer - utility as prognostic tools
Lung cancer is the leading cause of cancer-related deaths
worldwide and to date the role of miRNA in lung cancer
has been studied and reviewed extensively in comparison
to the other lung diseases. Lung cancer can be broadly
classified into small cell (SCLC) and non-small cell lung
cancer (NSCLC), the latter being more common can be
sub-classified into squamous and adenocarcinoma.
Approximately 15-20% of human cancers are heavily
associated with inflammation [68] where the involvement
of NF-B activation has been well documented [69].
Briefly, many miRNA identified as either tumor suppres-
sors or oncogenes in lung cancer are also reported to be
involved in the immune response, for example the let-7
family and the miR-17-92 cluster, respectively. Reduced
expression of the let-7 family members in human lung
cancer has been correlated with poor survival [70] and
delivery of exogenous let-7 to a mouse model of NSCLC
resulted in reduction of tumor load supporting a role for
this miRNA as a tumor suppressor [71]. The miR-17-92
cluster over-expressed in B cell lymphomas [72,73] was
found to be markedly increased in lung cancer by Haya-
shita et al in particular in those with SCLC histology [74]
and thus has been classified as an onco-miR. Down-
regulation of miR-126, also a proposed tumor suppressor
correlated with reciprocal expression of vascular
endothelial growth factor (VEGF) in eight lung cancer
cell lines and was shown to reduce tumor growth in a
xenograft mouse model [75].
With the detection of miRNA in blood cells and serum
as well as in tissue their value as potential diagnostic and
prognostic tools in cancer is emerging. Already in a study
of individuals with NSCLC, a five miRNA signature (con-
sisting of 2 protective miRNA - miR-221 and let-7a and 3
associated with poor prognosis miR-137, -372 and -182*)
has been identified for prediction of treatment outcome
[76]. MiRNA have demonstrated remarkable stability in
sputum where a combination of miR-21, -486, -375 and
-200b were shown to distinguish lung adenocarcinoma
from normal subjects with >80 and 90% sensitivity and
specificity respectively [77] and in serum where high
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levels of miR-141 discriminated individuals with prostate
cancer compared to controls [78]. Classification of lung
squamous cell carcinoma versus adenocarcinoma was
also reported based purely on detection of high levels of
miR-205 found in the former which are not present in
the latter [79].
Chronic obstructive pulmonary disease (COPD)
COPD is a disease predominantly induced by cigarette
smoking and/or chronic exposure to irritants. Emphyse-
matous lung disease in alpha-1 antitrypsin (a1-AT) defi-
cient individuals can also come under this heading.
Hallmarks of COPD include a progressive obstruction of
the airflow, chronic inflammation in the lungs, shortness
of breath, chronic cough and phlegm production [80,81].
COPD is classified as the 4th leading cause of death in
the US currently and is predicted to increase to 3rd place
by 2020 [82]. Both chronic inflammation in the airway
and systemic inflammation (potentially resulting from an
excess of pro-inflammatory mediators entering systemic
circulation) have been attributed to the pathogenesis of
COPD [83]. In particular, during exacerbations elevated
levels of numerous inflammatory markers such as inter-
leukin 6 (IL-6), IL-8, TNF-a and circulating activated
neutrophils have been reported [83]. These high levels of
primed neutrophils correlate with increased oxidative
stress and the severity of exacerbation [84].
The expression of miRNA in mouse and rat lungs
exposed to cigarette smoke extract (CSE) has been stu-
died by Izotti et al [85,86] where down-regulation of
miRNA was observed predominantly in both models.
Out of 484 miRNA analysed, 126 were down-regulated
by at least 2-fold and 24 ≥ 3-fold in smoke exposed rats,
with 15 down-regulated in mice compared to just one
and none up-regulated in the same animals. This is con-
sistent with the results of miRNA expression profiling in
human bronchial epithelium of 10 smokers versus 9
never smokers [87]. Twenty three miRNA were signifi-
cantly down-regulated and only 5 up-regulated out of a
total of 467 analysed in the smokers [87]. In silico analy-
sis of miRNA altered in mice exposed to CSE linked their
biological roles to a variety of functions including devel-
opment of airway epithelial cells, stress responses, forma-
tion of pulmonary surfactant and inflammation [86].
Many miRNA involved in activation of the NF-B path-
way such as miR-30, miR-146, miR-132 and miR-155
were down-regulated by CSE in rodents [86]. Contrary to
the CSE studies primary human bronchial epithelial cells
exposed to diesel exhaust particles (DEP) exhibited a pre-
dominant up-regulation (n = 130) compared to down-
regulation (n = 67) of miRNAs. Like cigarette smoke,
DEP has been linked to pulmonary inflammation,
increased risk of cancer and exacerbations in asthma and
COPD [88]. Bioinformatic analysis to determine the bio-
logical relevance of miRNA altered by DEP exposure
generated molecular networks enriched for inflammatory
pathways which correlated to IL-8, NF-B and CXCR4
signalling pathways. MiR-494 (increased ≥ 1.5 fold upon
DEP exposure) was predicted to have important roles in
NF-B and virus activated signalling [88].
Asthma
Asthma is a widespread complex disease affecting
approximately 300 million people worldwide [89]. Its
pathogenesis can be attributed to both genetic factors
and exposure to environmental triggers at various stages
of development ranging from pre-natal maternal expo-
sure to allergens through to occupational exposure in
adulthood for example [90]. Asthma is characterised by
chronic inflammation caused by persistent infiltration of
eosinophils and mast cells, an abnormal T helper-2
(TH2) response and the downstream actions of their
secreted cytokines. The TH2 cytokines IL-4, 5, 9 and 13
have all been linked to airway hyper-responsiveness
(AHR), mucus hypersecretion, eosinophil infiltration and
elevated levels of IgE [91,92]. Structural changes leading
to airway remodelling combined with chronic inflamma-
tion give rise to its hallmarks - reversible AHR and air-
way obstruction [93].
Focus on the role of miRNA in asthma has increased
recently with a number of studies in the past year report-
ing differential expression of miRNA in various models
of asthma. In a study of 579 miRNAs in bitransgenic
mice expressing IL-13 (a key TH2 derived cytokine) in a
lung specific manner, 21 were differentially expressed
upon induction of experimental asthma following treat-
ment with doxycycline [94]. The most up-regulated
miRNA was miR-21, with miR-1 being the most down-
regulated. These observations were replicated in two
other separate mouse models of experimental asthma
[94]. All three asthma models shared similar phenotypes
including AHR, mucus production and TH2 eosinophilic
inflammation and highest expression levels of miR-21
were observed in macrophages and dendritic cells. Inde-
pendently, Lu et al showed IL-4 transgenic mice demon-
strated increased expression of miR-21. IL-13-induced
expression of miR-21 was shown to be dependent on the
receptor IL-13Ra1, with allergen induced expression
mostly independent of this receptor. Up-regulation of
miR-21 correlated with down-regulation of its predicted
target IL-12p35 which was confirmed as a molecular tar-
get using a luciferase reporter system. Interestingly IL-12
derived from macrophages and dendritic cells is involved
in TH1 polarisation in the adaptive immune response
[95,96], suggesting that miR-21 may potentially regulate
a number of processes involved in allergic airway inflam-
mation [94]. Another study featuring IL-13 influences on
miRNA expression was performed by Chiba et al [97].
The monomeric GTP-binding protein RhoA has been
associated with contraction of smooth muscle, whereby
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its over-expression in an animal model of allergic bron-
chial asthma augmented contraction of bronchial smooth
muscle [98,99]. RhoA over-expression correlated with
down-regulation of miR-133a in human bronchial
smooth muscle cells (hBSM) treated with IL-13 and in
bronchial tissue from sensitised BALB/c mice repeatedly
challenged with ovalbumin [97]. This data suggests that
IL-13, one of the major up-regulated cytokines in asth-
matic airways, may play a role in AHR induction in part
through repression of miR-133a and inducing increased
expression of RhoA [97].
Surprisingly, expression profiling of 227 miRNA in air-
way biopsies from mild asthmatics before and after treat-
ment with the inhaled corticosteroid budesonide and also
compared to healthy non-asthmatics revealed no differ-
ences in miRNA expression [100]. However, analysis of a
range of cell types found within human lung (isolated
from a 5 donor pool) including macrophages, airway
smooth muscle cells, epithelial cells and fibroblasts
demonstrated miRNA profiles specific to particular cell
types. The majority of highly expressed miRNA were
contained within alveolar macrophages compared to
other cell types, in particular miRs -30a-5p, -92, -142-3p,
-146b, -191, -223 , -320 and -342. In order to explain
this, the authors proposed that differential miRNA
expression may occur in mild asthmatics possibly within
specific cells types which could have been masked in the
airway biopsies tested due to the presence of multiple
cell types. Potentially in more severe cases of asthma, dif-
ferential miRNA expression might be more evident [100].
Cystic fibrosis (CF)
CF is one of the commonest lethal genetic diseases in
Caucasians with approximate incidences of 1:3500 in
Europe and North America. CF is also evident in Afri-
can and Asian populations albeit to a much lesser
degree (1:5000 - 1:20,000) [101]. Despite significant
advances in treatment regimes CF remains a condition
for which there is no effective cure with >90% of deaths
occurring as a result of respiratory failure [102]. Follow-
ing establishment of CF as a disease with altered chlor-
ide ion transport the gene responsible for the cause of
CF (CF transmembrane conductance regulator - CFTR)
was discovered in 1989 [103,104]. There have been over
1400 disease-causing mutations identified to date in the
CFTR gene and these can be generally grouped into six
classes based on cellular phenotype [105]. Δ508 which
falls into class II is the most prevalent mutation world-
wide [106].
CF lung disease is characterised by chronic infection,
exaggerated intra-pulmonary protease levels e.g. neutro-
phil elastase (NE) and neutrophil dominated airway
inflammation. Impaired chloride ion channel secretion
results in a build up of thick sticky mucus and reduced
mucocilary clearance leading to bacterial colonisation
with bacteria such as Pseudomonas aeruginosa. The
gram-negative bacterial cell wall component LPS and
IL-1b, which bind to Toll-Like Receptor 4 (TLR4) and
the IL-1 Type-I receptor (IL-1RI), respectively, play a
pivotal role in this process. These agonists can activate
the innate immune response culminating in pro-inflam-
matory gene expression leading to infiltration of large
numbers of neutrophils contributing to sustained endo-
bronchial inflammation and tissue damage in the CF
lung. In the context of CF airway epithelial cells both
the IL-1RI and TLRs have been shown to promote pro-
inflammatory gene transcription following stimulation
with their cognate agonists [107,108]. For example, in
airway epithelial cells of non-CF and CF origin triacy-
lated lipopeptide, LPS or unmethylated CpG DNA can
induce IL-6, IL-8 and TNF-a production via TLRs 2, 4
and 9 [107]. Similarly, IL-1b can up-regulate production
of a plethora of pro-inflammatory cytokines [108]. Thus
IL-1RI and/or TLRs and their signalling intermediates
represent potential therapeutic targets for CF. Accumu-
lation of neutrophils with impaired function, their sub-
sequent degradation and release of intracellular contents
including NE contributes greatly to sustained protease-
antiprotease imbalance [109] and damage to structural,
cellular and soluble components of the CF lung [110].
NE has also been shown to induce IL-8 expression via
MyD88/IRAK/TRAF6 pathways in human bronchial
epithelium [111].
We have previously reported differential expression of
miRNA in CF whereby expression profiling of 667 dif-
ferent human miRNAs was performed on bronchial
brushings taken from CF and non-CF individuals (n = 5
each) by qRT-PCR, [112]. Expression of 391 miRNAs
was detected across all samples with 56 being down-
regulated (Relative Quantification (RQ) ≤ 0.7) and 36
up-regulated (RQ ≥ 1.5) in CF versus non CF controls.
Expression of miR-218 remained unchanged in the
bronchial epithelium of CF versus non-CF individuals
[112], however it was found to be the most significantly
down-regulated miRNA in bronchial epithelial cells of
smokers vs. non- smokers in a study by Shembri et al
[87] providing support of the phenomenon of disease-
specific expression of miRNA. Consistent with a report
of miR-494 up-regulation in bronchial epithelial cells
exposed to DEP [88] we also found this miRNA to be
up-regulated in CF versus non-CF bronchial brushings
[112]. MiR-126, discussed in the following section, was
found to be significantly decreased in four of the five CF
samples compared to controls. We are currently pursu-
ing the role of a selection of miRNA and their predicted
biological targets resulting from follow-up in silico ana-
lysis, with a view to uncovering previously unidentified
regulatory mechanisms that may control changes in
gene expression and direct the development of future
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therapeutic strategies, possibly directed at IL-1RI/TLR
signalling, for this debilitating and fatal disorder.
miR-126 in CF and asthma - a key innate immune
regulator?
MiR-126 is 21 nucleotides in length, located on chromo-
some 9q34.3 and is contained within intron 5 of its host
gene epidermal growth factor like-7 (EGFL-7) [113]. It
has previously been shown to have functional roles in
angiogenesis [26,27], to be down-regulated in a number
of malignancies [23,114] and to act as a tumor suppres-
sor in breast cancer [28]. We selected miR-126 for
further investigation following miRNA expression profil-
ing in CF vs. non-CF bronchial brushings given that its
expression is known to be highest in vascularised tissues
such as the lung, heart and kidney [113,115,116] and as
it has been shown to be present in bronchial epithelium
[114]. We found down-regulation of miR-126 in CF
bronchial epithelial cells correlated with a significant
up-regulation of TOM1 mRNA when compared to their
non-CF counterparts. TOM1 (target of Myb1) has been
shown to interact with Toll interacting protein (Tollip),
forming a complex to regulate endosomal trafficking of
ubiquitinated proteins. TOM1 has also been proposed
as a negative regulator of IL-1b and TNF-a induced sig-
nalling pathways [117-119]. Over-expression of miR-126
decreased TOM1 protein production in CF bronchial
epithelial cells and decreased luciferase activity in a
reporter gene containing the full length 3’UTR of
TOM1 demonstrating direct targeting. Following stimu-
lation with LPS or IL-1b, over-expression of TOM1 was
found to down-regulate NF-B luciferase activity. Con-
versely, TOM1 knockdown resulted in a significant
increase in NF-B regulated IL-8 secretion suggesting
that miR-126 may have an important role in regulating
innate immune responses in the CF lung.
Neither LPS nor IL-1b alone had any effect on miR-
126 expression and similarly Harris et al showed miR-
126 was not altered in response to TNF-a [113]. They
reported miR-126 inhibits vascular cell adhesion mole-
cule 1 (VCAM1) in vitro and proposed a regulatory role
for miR-126 in inflammation, specifically in the vascula-
ture. A role for miR-126 in the pathogenesis of allergic
asthma was described by Mattes et al who showed
increased expression levels of miR-16, -21 and -126 in
the lower airway tissue isolated from a BALB/c mouse
model of allergic asthma induced by house dust mite
(HDM) challenge. Inhibition of miR-126 resulted in
abrogation of the asthmatic phenotype as demonstrated
by a reduction in AHR, inflammation, TH2 responses,
mucus hypersecretion and eosinophil recruitment. They
concluded that miR-126 expression is dependent on
both the TLR4 and MyD88 pathways as they failed to
detect its up-regulation in the airways of either TLR4 or
MyD88 deficient mice. These mice failed to display any
of the hallmark features of asthma despite repeated
allergen challenge [120]. Further analysis of miR-126
inhibition in airway walls of HDM sensitised mice
revealed significant up-regulation of Oct binding factor
1 (OBF.1), known to be a critical regulator of the tran-
scription factor PU.1 which can negatively regulate TH2
responses and TLR4 expression through suppression of
GATA3 [121,122]. Notably the suppression of TH2
responses occurred in the absence of a TH1 response,
indicating specific targeting of the TH2 regulated inflam-
matory response by miR-126 in allergic lung disease
[120]. Taken together with our data this supports an
important role for miR-126 in the innate immune
response of the lung.
Idiopathic pulmonary fibrosis (IPF)
IPF is a progressive disease of the lung interstituim
characterised by epithelial cell injury, fibroblast prolif-
eration and excessive accumulation of extracellular
matrix proteins such as collagen within the lung par-
enchyma. This is usually accompanied by increased
levels of the key fibrotic mediator transforming growth
factor b (TGF-b) and other cytokines produced at the
site of active fibrosis [123]. Evidence of miRNA involve-
ment in the pathogenesis of IPF is just starting to
emerge with a number of recent studies describing dif-
ferential miRNA expression. Pottier et al compared
miRNA expression profiles of normal lung fibroblasts
with alveolar epithelial cells and found a selection of
miRNA were preferentially expressed in fibroblasts.
Expression of miR-155 was up-regulated in the presence
of TNF-a and IL-b with a concomitant reduction of
keratinocyte growth factor (KGF) in normal pulmonary
fibroblasts leading to increased fibroblast migration via
activation of caspase 3. Following treatment with TGF-
b, miR-155 levels were reduced. In a mouse model of
fibrosis miR-155 levels correlated with the degree of
fibrosis [123]. Expression profiling of human IPF lung
tissue biopsies compared with controls revealed differen-
tial expression of 46 miRNA. Of those, 18 were signifi-
cantly down-regulated including miR-126, miR-203,
several members of the miR-30 family and let-7d. Again
TGF-b was found to decrease let-7d which correlated
with an up-regulation of its predicted target HMGA2.
Knock down of let-7d resulted in increased levels of col-
lagen and alveolar septal thickening in mouse lungs
in vivo and epithelial mesenchymal transition in vitro
[124]. The oncogenic miR-21 was also observed to play
a role in IPF whereby it was found to be up-regulated in
human IPF samples and in the lungs of mice with bleo-
mycin induced fibrosis. Enhanced miR-21 expression
was observed in primary pulmonary fibroblasts treated
with TGF-b. Inhibition of miR-21 decreased the severity
of fibrosis whereas over-expression promoted TGF-b
induced fibrotic activity [125].
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Conclusion
Intensive research over the past decade has rapidly
advanced our knowledge of miRNA participation in
numerous biological processes and disease states. It is
clear that both appropriate miRNA regulation and inap-
propriate dysregulation forms a major part of mamma-
lian development and disease progression respectively. In
the early stages of miRNA discovery it was predicted that
they could potentially regulate up to one third of the
human genome which is probably largely underestimated
with some target prediction databases suggesting thou-
sands of potential targets for certain miRNA. One single
miRNA has the capacity to regulate hundreds of targets
and likewise individual target genes may be regulated by
several miRNA depending on the amount of MREs they
possess. Questions remain as to whether preferential
binding of certain miRNA occurs, i.e. are some miRNA
more dominant than others? A number of profiling stu-
dies have reported that the majority of differentially
expressed miRNA in disease states are down-regulated
[85-87]. We observed this to be the case in CF where
almost twice as many miRNA were down-regulated com-
pared to up-regulated versus non-CF controls. Upon
in silico analysis for a number of target genes of particu-
lar interest to our laboratory we found several predicted
to be regulated by an equal number of both up- and
down regulated miRNA, suggesting possible maintenance
of a balance of gene expression.
In summary, we have outlined some of the evidence
identifying miRNA as key regulators of the innate
immune response with particular reference to TLR4 sig-
nalling and negative feedback control of inflammation
where both miRNA and transcription factors can regulate
one another to maintain a stable cellular environment
and whereby irregular expression can contribute to
inflammatory disease progression. We discuss miRNA
involvement in lung cancer and also describe the emer-
ging role of miRNA in the progression of inflammatory
lung diseases such as CF, COPD, asthma and IPF. The
dysregulation of miRNA in chronic inflammatory lung
disease represents an exciting possibility for therapeutic
intervention however the development of strategies har-
nessing miRNA expression for treatment of these dis-
eases is at an early stage and will take some time to
optimise delivery, stability and specificity. Targeting
miRNA expression in the lung may represent a realistic
therapeutic intervention as aerosolisation enhances drug
delivery to the site of action and decreases systemic expo-
sure of the patient to the therapy, thereby reducing off-
target effects. However the nucleic acid-based molecules
used for miRNA modulation are large negatively charged
moieties and these physicochemical properties limits
intracellular delivery to their sites of action. In the
meantime several challenges remain for investigators to
fully elucidate the functional relevance of miRNA:
mRNA interactions, to assess the impact of target gene
regulation by several miRNA to establish if preferential
binding/synergistic repression exists and also to establish
the mechanism for clearance of miRNA from the cell, all
of which will help define miRNA regulation in complex
cellular systems and facilitate the development of specific
therapeutic approaches.
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